



Dear CGD Community,

We would like to begin by sincerely thanking the CGD community for the warmth, openness, and collaboration you have extended to Prime Medicine. Over the past year, we have learned so much from you—about your experiences, your resilience, and your hopes for the future. Meeting families, speaking with physician experts, and partnering with dedicated patient advocacy organizations has been an honor and a source of deep inspiration for our team.

We wanted to make you aware of some important news shared on May 19<sup>th</sup>, 2025, by our organization regarding both an update to the CGD Program, and Prime Medicine as a whole. First, we want to share that the initial clinical data from our PM359 program for CGD has been very encouraging. You can read more details about this early data in our press release here:

<https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-breakthrough-clinical-data-showing>. These early results reflect the potential of Prime Editing to make a meaningful difference in the lives of patients and families affected by this disease.

Despite these encouraging results, however, after careful consideration, we have made the difficult decision to discontinue internal development of the PM359 program. We want to be clear that this decision is not related to safety concerns or lack of scientific promise. Rather, it is the result of assessing our programs amidst the current external environment and a need to streamline our areas of pipeline focus accordingly.

We know how disappointing this news is, especially given the early promise shown by these initial results. Please know that we remain committed to finding a path forward for this potential treatment. We are actively exploring partnership opportunities with the goal of ensuring that PM359 can continue development and ultimately become accessible to the CGD community via a partner who is able to dedicate the resources to move it forward. We will provide potential updates through our corporate press releases on our website and will update our Patient Advocacy partners accordingly.

We would also like to recognize and thank the incredible CGD patient advocacy organizations whose work has had a profoundly positive impact on our efforts. The CGD Association of America, CGD Society UK, Immune Deficiency Foundation, and IPOPI have each played a critical role in advancing awareness, education, and support for individuals and families affected by CGD. Their leadership, insight, and dedication have helped guide our work and ensured that the voices of patients and caregivers remained at the heart of our program.

With Gratitude,  
Prime Medicine

Prime Medicine  
60 First Street  
Cambridge, MA 02141